Healthcare Industry News: hemodialysis
News Release - June 7, 2007
Daxor Announces Oklahoma VA Medical Center of Oklahoma City, OK Acquires BVA-100 Blood Volume AnalyzerNEW YORK, NY--(Healthcare Sales & Marketing Network)--Jun 7, 2007 -- Daxor Corporation (AMEX:DXR ), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from the Oklahoma City Department of Veterans Affairs Medical Center (VAMC) of Oklahoma City, Oklahoma.
The Oklahoma City VAMC is a 169-bed facility that serves as a primary, secondary and tertiary care center for eligible veterans in the greater Oklahoma City metropolitan area and the western two-thirds of the state, and two counties in north central Texas. It is a regional referral center for open-heart surgery and hemodialysis, and has active affiliations with the University of Oklahoma Medical School. Classified as a Clinical Referral Level III facility, the Oklahoma City VA Medical Center is a teaching hospital, providing a full range of patient care services with state-of-the-art technology.
Daxor's Blood Volume Analyzer BVA-100 will be located within the Oklahoma VAMC's Nuclear Medicine Department. The BVA-100 will be utilized to measure, diagnose and treat blood volume abnormalities in various medical conditions and disease states. A June 2007 article published in the Journal of Nuclear Medicine Technology discusses the constant estimation by indirect and often misleading surrogate measurements by clinicians to determine if a patient is "wet" or "dry." Patients who are "wet" are treated with diuretics and various fluid removal/restrictive practices, while "dry" patients receive intravenous fluids or blood transfusions. An incorrectly diagnosed and treated blood volume abnormality may be extremely detrimental to a patient's health. Daxor's BVA-100 removes the guess work of surrogate and indirect estimates by directly measuring a patient's blood volume to diagnose the blood volume and provide a guide for precise treatment. Previous published studies in peer reviewed medical journals have demonstrated improved outcomes when a patient's blood volume is properly diagnosed and treated.
Other hospitals which have purchased the BVA-100 Blood Volume Analyzer following a trial agreement are the Mayo Clinic; Cleveland Clinic; and the VA Medical Center of Puerto Rico. Daxor Corporation manufactures and markets the BVA-100, the only FDA approved semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.